⌕
Compass Pathways · CMPS · Nasdaq
Tenet — · insufficient data
Compare
$8.27−8.21%At close
$8.27−0.74 (−8.21%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
Data under review. Our nightly checks found a problem in this company's reported figures on Oct 23, 2026, so we are not showing its score, ratios or statements for now. The figures come back after they pass the checks two nights in a row. The price and chart are live.

Compass Pathways (CMPS) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● MarketBeatNov 12, 2026 · 06:14 ET
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch

Compass Pathways NASDAQ: CMPS has completed its application for U.S. approval of COMP360, its proprietary synthetic psilocybin formulation for treatment-resistant depression, and is preparing for a potential commercial l…

● Business WireNov 11, 2026 · 06:30 ET
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced t…

● Business WireNov 9, 2026 · 06:30 ET
Compass Pathways Completes COMP360 Psilocybin New Drug Application to U.S. FDA for Treatment-Resistant Depression

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today annou…

● Business WireNov 5, 2026 · 16:30 ET
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced t…

● Defense WorldNov 5, 2026 · 01:16 ET
Compass Pathways Q3 Earnings Call Highlights

Compass Pathways (NASDAQ: CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within two weeks, as the c…

● Business WireNov 4, 2026 · 06:30 ET
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced t…

● The Motley FoolNov 3, 2026 · 23:31 ET
Compass Pathways: 3 Key Takeaways for Long-Term Investors

COMPASS will complete its New Drug Application submission within two weeks. Interventional psychiatrists surveyed show 90% willingness to prescribe COMP360.…

● Seeking AlphaNov 3, 2026 · 12:45 ET
COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript

COMPASS Pathways plc (CMPS) Q3 2026 Earnings Call Transcript…

● Business WireNov 3, 2026 · 06:30 ET
Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today repor…

● Business WireNov 2, 2026 · 06:30 ET
New Joint Survey from Compass Pathways and the Depression and Bipolar Support Alliance Reveals the Lived Burden of Treatment-Resistant Depression on Patients and Caregivers

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, in partners…

● The Motley FoolNov 2, 2026 · 03:30 ET
1 Reason Compass Pathways Is Worth a Second Look This Month

FDA approval could provide a significant catalyst for shares. Wall Street's average price target implies approximately 95% upside.…

● Business WireOct 28, 2026 · 06:30 ET
Compass Pathways to Highlight Scientific Research and TRD Disease State Education Efforts at the 2026 Neuroscience Education Institute Fall Congress

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today annou…

● Seeking AlphaOct 28, 2026 · 01:11 ET
Compass Pathways: A Compelling Opportunity In A Large And Underserved Market

COMPASS Pathways is currently engaged in a rolling submission and review with the FDA for COMP360 and expects a commercial launch in the first half of 2027. COMPASS is initially targeting the TRD market, which is large a…

● Business WireOct 27, 2026 · 06:30 ET
Compass Pathways to Announce Third Quarter 2026 Financial Results on November 3, 2026

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced t…

● Seeking AlphaOct 21, 2026 · 10:17 ET
Compass Pathways: Built The FDA's Way, Valued At 0.57x Spravato's Sales

COMPASS Pathways is rated Buy, with high risk, based on strong trial design and imminent FDA review for COMP360 in treatment-resistant depression. COMP360's Phase 3 trials matched FDA guidance, achieved statistically sig…

● Business WireOct 14, 2026 · 06:30 ET
Compass Pathways Joins Forces with Leading Mental Health Organizations to Mark First-Ever U.S. Treatment-Resistant Depression (TRD) Awareness Day

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, today annou…

● Business WireOct 2, 2026 · 06:30 ET
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that…

● Defense WorldOct 1, 2026 · 04:29 ET
Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Stock Has Consensus Target Price of $23.36 According to Brokerages

Compass Pathways PLC Sponsored ADR (NASDAQ: CMPS - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seventeen brokerages that are currently covering the company, MarketBeat reports.…

● Business WireSep 30, 2026 · 06:30 ET
Compass Pathways Appoints Kelley Boucher as Chief People Officer

LONDON & NEW YORK--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced the appoin…

● MarketBeatSep 24, 2026 · 20:02 ET
Compass Pathways Targets Q4 COMP360 NDA Completion, Eyes 2027 Launch

Compass Pathways NASDAQ: CMPS executives said the company remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter, while preparing commercial infrastructure for a potent…

● Defense WorldSep 24, 2026 · 02:03 ET
Compass Pathways Eyes 2027 COMP360 Launch as FDA Review Advances

Compass Pathways (NASDAQ: CMPS) expects to complete its new drug application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, in the fourth quarter, with a potential U.…

● MarketBeatSep 22, 2026 · 17:02 ET
Compass Pathways Targets 2027 COMP360 Launch After Positive Phase III Depression Data

Compass Pathways NASDAQ: CMPS said it remains on track to complete its rolling New Drug Application submission for COMP360 in the fourth quarter of 2026, following positive Phase III studies of its synthetic psilocybin t…

● MarketBeatSep 22, 2026 · 02:02 ET
Compass Pathways Eyes 2027 COMP360 Launch as FDA Filing Nears

Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for its synthetic psilocybin treatment, COMP360, in the fourth quarter and continues to target a potential commercial …

No recent releases where the company itself is speaking.

Kept in their own lane. A press release is the company talking, not reporting.

No upcoming events in the feeds.

Article counts from the last market-wide feed page, across every symbol we track and not just CMPS · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.